Skip to main content
Livermore
Livermore
ZHEN

Barclays PLC

SEC CIK
0000312069
Latest filing
Aug 14, 2026

KALV holding history

KalVista Pharmaceuticals, Inc. in every 13F filed by Barclays PLC, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.

KALV overviewAll 13F holders of KALVFull Q2 2026 holdings

Shares (Q2 2026)
0
Sold out in Q2 2026
Value
$0
% of portfolio
0.0%
Quarters held
21
Since Q1 2021
Holdings of KALV by Barclays PLC, by quarter
QuarterSharesValue% of portfolioShare changeActionAll holders
Q2 20260$00.0%−537,061−100.0%Sold outHolders
Q1 2026537,061$10.8M<0.1%−163,512−23.3%ReducedHolders
Q4 2025700,573$11.3M<0.1%+122,669+21.2%AddedHolders
Q3 2025577,904$7.04M<0.1%+408,981+242.1%AddedHolders
Q2 2025168,923$1.91M<0.1%+113,696+205.9%AddedHolders
Q1 202555,227$637.3K<0.1%−12,835−18.9%ReducedHolders
Q4 202468,062$576.5K<0.1%+840+1.2%AddedHolders
Q3 202467,222$778.4K<0.1%+54,257+418.5%AddedHolders
Q2 202412,965$152.7K<0.1%−8,990−40.9%ReducedHolders
Q1 202421,955$260.4K<0.1%−20,576−48.4%ReducedHolders
Q4 202342,531$521.0K<0.1%+38,316+909.0%AddedHolders
Q3 20234,215$40.6K<0.1%−691−14.1%ReducedHolders
Q2 20234,906$44.2K<0.1%−7,507−60.5%ReducedHolders
Q1 202312,413$97.6K<0.1%+5,841+88.9%AddedHolders
Q4 20226,572$44.4K<0.1%+3,923+148.1%AddedHolders
Q3 20222,649$38.0K<0.1%+679+34.5%AddedHolders
Q2 20221,970$19.0K<0.1%−1,668−45.8%ReducedHolders
Q1 20223,638$54.0K<0.1%−25,348−87.4%ReducedHolders
Q4 202128,986$383.0K<0.1%+18,582+178.6%AddedHolders
Q3 202110,404$181.0K<0.1%+5,335+105.2%AddedHolders
Q2 20215,069$122.0K<0.1%−28,214−84.8%ReducedHolders
Q1 202133,283$854.0K<0.1%––Holders

Livermore's 13F data starts with Q1 2021, so Q1 2021 has no change from the previous quarter.